Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
Same here | Count Crypto | investorshub | 09/30/2023 11:24:11 AM |
$OKYO good read | Sirpeter | investorshub | 09/30/2023 9:50:54 AM |
$OKYO What do you make of this? | Count Crypto | investorshub | 09/30/2023 8:37:11 AM |
The now | mfayman | investorshub | 09/30/2023 6:18:09 AM |
The gaining last up | mfayman | investorshub | 09/30/2023 5:49:59 AM |
$OKYO oh yeah news for the day | mfayman | investorshub | 09/30/2023 4:50:19 AM |
$OKYO MomentumIts trading last trade up | mfayman | investorshub | 09/30/2023 3:14:10 AM |
$OKYO Price now last up | glenn1919 | investorshub | 09/30/2023 2:28:15 AM |
$OKYO short squeeze | Sirpeter | investorshub | 09/30/2023 12:46:10 AM |
The gaining up | mfayman | investorshub | 09/30/2023 12:32:02 AM |
just the news we needed | glenn1919 | investorshub | 09/30/2023 12:21:31 AM |
$OKYO MomentumIts trading last up | mfayman | investorshub | 09/29/2023 11:33:51 PM |
bears and bulls | mfayman | investorshub | 09/29/2023 11:00:54 PM |
$OKYO Price now | mfayman | investorshub | 09/29/2023 9:33:31 PM |
Not a bad week. On watch | Ryguy008 | investorshub | 09/29/2023 9:28:07 PM |
$OKYO oh yeah news for the day | Pisd | investorshub | 09/29/2023 9:23:24 PM |
The now | Sirpeter | investorshub | 09/29/2023 9:22:26 PM |
Once we break thru 2$+ were gonna be | mfayman | investorshub | 09/29/2023 9:17:35 PM |
I would say so! Making higher highs and | mfayman | investorshub | 09/29/2023 9:15:05 PM |
Seems ready | Count Crypto | investorshub | 09/29/2023 9:14:15 PM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...